Angitia Biopharmaceuticals Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 63

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $130M

  • Investors
  • 24

Angitia Biopharmaceuticals General Information

Description

Operator of a global clinical-stage biotechnology company intended for the discovery and development of breakthrough therapies. The company focuses on the research and development of drugs for bone, muscle, and joint diseases, with innovative drugs, enabling patients to recover from severe musculoskeletal diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3027 Townsgate Road
  • Suite 220
  • Westlake Village, CA 91361
  • United States
+1 (818)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3027 Townsgate Road
  • Suite 220
  • Westlake Village, CA 91361
  • United States
+1 (818)

Angitia Biopharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Angitia Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 27-Jan-2026 $130M Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C) 03-Dec-2024 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series B1) 01-Jan-2024 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series B) 30-Oct-2021 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 17-Aug-2020 $30M $45M Completed Clinical Trials - Phase 2
1. Seed Round 27-Jun-2018 $15M $15M Completed Startup
To view Angitia Biopharmaceuticals’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Angitia Biopharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a global clinical-stage biotechnology company intended for the discovery and development of breakthrough the
Drug Discovery
Westlake Village, CA
63 As of 2026

Cambridge, MA
 

Richmond, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Angitia Biopharmaceuticals Competitors (83)

One of Angitia Biopharmaceuticals’s 83 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Capricor Therapeutics Formerly VC-backed San Diego, CA
Kolon TissueGene Corporation Rockville, MD
Aldeyra Therapeutics Formerly VC-backed Lexington, MA
You’re viewing 5 of 83 competitors. Get the full list »

Angitia Biopharmaceuticals Patents

Angitia Biopharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12630651-B2 Anti-sclerostin constructs and uses thereof Active 28-Sep-2020
US-20230312755-A1 Anti-sclerostin constructs and uses thereof Active 28-Sep-2020
US-20260201071-A1 Anti-sclerostin constructs and uses thereof Pending 28-Sep-2020
WO-2022063262-A1 Anti-sclerostin constructs and uses thereof Inactive 28-Sep-2020 A61P19/00

Angitia Biopharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Angitia Biopharmaceuticals Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ascenta Capital Venture Capital Minority
BlackRock Asset Manager Minority
BVF Partners Hedge Fund Minority
Frazier Healthcare Partners PE/Buyout Minority
Logos Capital Hedge Fund Minority
You’re viewing 5 of 24 investors. Get the full list »

Angitia Biopharmaceuticals FAQs

  • When was Angitia Biopharmaceuticals founded?

    Angitia Biopharmaceuticals was founded in 2018.

  • Where is Angitia Biopharmaceuticals headquartered?

    Angitia Biopharmaceuticals is headquartered in Westlake Village, CA.

  • What is the size of Angitia Biopharmaceuticals?

    Angitia Biopharmaceuticals has 63 total employees.

  • What industry is Angitia Biopharmaceuticals in?

    Angitia Biopharmaceuticals’s primary industry is Drug Discovery.

  • Is Angitia Biopharmaceuticals a private or public company?

    Angitia Biopharmaceuticals is a Private company.

  • What is Angitia Biopharmaceuticals’s current revenue?

    The current revenue for Angitia Biopharmaceuticals is .

  • How much funding has Angitia Biopharmaceuticals raised over time?

    Angitia Biopharmaceuticals has raised $420M.

  • Who are Angitia Biopharmaceuticals’s investors?

    Ascenta Capital, BlackRock, BVF Partners, Frazier Healthcare Partners, and Logos Capital are 5 of 24 investors who have invested in Angitia Biopharmaceuticals.

  • Who are Angitia Biopharmaceuticals’s competitors?

    Sarepta Therapeutics, Sangamo Therapeutics, Capricor Therapeutics, Kolon TissueGene, and Aldeyra Therapeutics are some of the 83 competitors of Angitia Biopharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process